Partnerships & Alliances
Filter News
Found 49,512 articles
-
OnGen LIMS Partners with SafelyThrive, Creating the Most Advanced COVID-19 Protection Program Available
6/23/2021
Advanced laboratory information management system (LIMS), OnGen, has been named the exclusive LIMS of SafelyThrive.
-
Pacific Biosciences and Rady Children’s Institute for Genomic Medicine Announce its First Research Collaboration for Whole Genome Sequencing
6/23/2021
Pacific Biosciences of California, Inc. (Nasdaq: PACB)(“Pacific Biosciences” or “PacBio”), and Rady Children’s Institute for Genomic Medicine (RCIGM), shared today that they are collaborating on a study which aims to identify potential disease-causing genetic variants and increase the solve rates of rare diseases.
-
Veradigm and PRA Health Sciences Partner to Create the Industry’s Leading EHR-Based Clinical Research Network
6/23/2021
Veradigm®, and PRA Health Sciences, Inc. (NASDAQ: PRAH), announced today the creation of the industry’s leading electronic healthcare records-based clinical research network that reaches more than 25,000 physicians and 40 million patients across the United States.
-
Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III
6/23/2021
Chemomab Therapeutics, Ltd. (NASDAQ: CMMB), and AGC Biologics, today announced an expanded partnership to manufacture CM-101, a Phase II investigational drug targeting Primary Sclerosing Cholangitis, Systemic Sclerosis, and Liver Fibrosis MoA (NASH).
-
Pear Therapeutics and Serve You Rx Announce Formulary Coverage for Prescription Digital Therapeutic Somryst® and People with Chronic Insomnia
6/23/2021
Pear Therapeutics and Serve You Rx Announce Formulary Coverage for Prescription Digital Therapeutic Somryst ® and People with Chronic Insomnia
-
M2S and NAMSA Collaboration to Nest Pre-market Vascular Device Trials in Registries
6/23/2021
A strategic collaboration has been established to combine the medical registry services of M2S, a division of Medstreaming, with the Contract Research Organization (CRO) expertise of NAMSA, to provide more efficient clinical trial services for vascular device manufacturers.
-
CCT Research and Commonwealth Primary Care ACO Team Up to Increase Clinical Trial Access for Arizona Patients
6/23/2021
CCT Research, an innovative site network that supports clinical research in the fields of Neurology, Family Practice, Dermatology, and Illness Prevention, has announced a new partnership with Commonwealth Primary Care ACO, an Arizona-based Accountable Care Organization with a network of 24 sites and more than 130 independent physicians throughout the state.
-
Cohen Veterans Bioscience Joins PRISM 2 Consortium
6/23/2021
Brain research and advocacy non-profit Cohen Veterans Bioscience (CVB) announced today that it joined the PRISM 2 consortium as as a designated associated partner of the Innovative Medicines Initiative (IMI).
-
Cerecor Licenses Immune Checkpoint Program from Sanford Burnham Prebys Further Expanding Pipeline of Immunology and Immuno-oncology Targets
6/23/2021
Cerecor Inc. today announced that it has entered into an exclusive license agreement with Sanford Burnham Prebys for the worldwide development and commercialization of an immune checkpoint program.
-
Conformis, Inc. Announces Exclusive Distribution Agreement in ChinaNew Agreement expands Conformis’ global reach and brings patient-specific knee replacement systems to the largest market in the Asia-Pacific region
6/23/2021
Conformis, Inc. (NASDAQ:CFMS) today announced the execution of an agreement to enter the Asia-Pacific market through an exclusive distribution relationship with XR Medical Group (Hong Kong) Limited (XR Medical).
-
SpineCraft and Wishbone Medical Enter Distribution Agreement to Increase Access to Comprehensive Spine Deformity System for Pediatric Orthopedic Market
6/23/2021
SpineCraft, LLC and WishBone Medical, Inc. announced a long-term distribution agreement pursuant to which WishBone will distribute SpineCraft’s ASTRA Spine Deformity System in several U.S. markets—with focus on the pediatric spine deformity segment.
-
Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021
6/23/2021
Brii Biosciences today announced final results from a Phase 1b/2a study on BRII-179 (VBI-2601), a novel recombinant, protein-based immunotherapeutic candidate, in patients with chronic hepatitis B virus (HBV) infection.
-
Valent BioSciences and Valent U.S.A. Collaborate with Halo on Open Innovation Initiative Seeking New Technologies and Solutions
6/23/2021
Valent BioSciences and Valent U.S.A. are collaborating with Halo to launch an open innovation initiative utilizing Halo’s state-of-the-art technology platform.
-
The Joint Commission and the American College of Obstetricians and Gynecologists announce new collaboration to address maternal health
6/23/2021
The Joint Commission and the American College of Obstetricians and Gynecologists announced a new collaboration to help reduce maternal mortality and morbidity in the United States through the development of a new Maternal Levels of Care Verification Program, available Jan. 1, 2022.
-
Aleta Biotherapeutics and Cancer Research UK Collaborate to Advance Blood Cancer Therapy Into the Clinic
6/23/2021
Aleta Biotherapeutics and Cancer Research UK announced a collaboration to advance the early phase clinical development of Aleta’s CAR-T cell engager candidate, ALETA-001.
-
Recursion Announces Multi-Year Collaboration with Mila for Tech-Enabled Drug Discovery
6/23/2021
Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced a multi-year collaboration with Mila, the Quebec Artificial Intelligence Institute, to accelerate Recursion's machine learning capabilities.
-
Cantex forges a licensing deal with vTv Therapeutics and intends to evaluate the vTv drug as a potential treatment for several cancer-related issues.
-
As part of the announcement, TRexBio indicated that Johnston Erwin had been appointed CEO and Ovid Trifan would be the company’s CMO.
-
Halozyme revealed that ViiV will pay $40 million upfront for the exclusive license to four small and large molecule targets and then pay the remaining $175 million in milestones.
-
JanOne Selects Regulatory Partner for Phase 2b Trial as Investigational Plan is Prepared for FDA Filing
6/22/2021
Global Contract Research Organization (CRO) Avania to Manage All Regulatory Affairs in Connection with JanOne's Phase 2b Trial Preparedness and Execution